RetaCalc
Protocol library
SinglePreclinicalPreclinicalVery Low confidenceSourced

IGF-1 LR3

A long-acting IGF-1 research analogue used mainly in laboratory models. Clinical evidence for approved recombinant human IGF-1 does not transfer to LR3.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 1 mg research vial

20 mcg daily in weeks 1-2, 40 mcg in weeks 3-4 and 50 mcg in weeks 5-8

No controlled human LR3 study validates this schedule. Evidence for authorised mecasermin or native IGF-1 is not molecularly interchangeable.

View source

Evidence summary

A long-acting IGF-1 research analogue used mainly in laboratory models. Clinical evidence for approved recombinant human IGF-1 does not transfer to LR3.

Protocol basis

The protocol boundary is molecular identity. Evidence from mecasermin labels or native IGF-1 cannot be used to manufacture a human LR3 schedule.

What remains uncertain

Human pharmacokinetics, safety, dose-response, long-term growth effects and clinical benefit are unknown.

Warnings and contraindications

IGF-1 LR3 is not the same molecule as authorised mecasermin.
No controlled human LR3 administration protocol was identified.
IGF signalling can affect glucose, tissue growth and multiple organ systems.